Related Pages for DRREDDY
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Price vs OI
- Time Series
- Volatility Skew
- Premium Decay
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
DRREDDY
1374.1
Related News - DRREDDY
Dr Reddy's: Faces Challenges As Apotex Gets Approval For Generic Wegovy, Risking GLP-1 Market Potential; Citi Signals Downside, Keeps 'Sell' Rating With ₹1,070 Target.
01 Jul 2026 12:04 PM
Dr Reddy's: Faces Challenges As Apotex Gets Approval For Generic Wegovy, Risking GLP-1 Market Potential; Citi Signals Downside, Keeps 'Sell' Rating With ₹1,070 Target.
Dr. Reddy’s Laboratories: Co to Consider Q1 Results on July 22
01 Jul 2026 09:36 AM
Dr. Reddy’s Laboratories: Co to Consider Q1 Results on July 22
Dr. Reddy's Lab: Jefferies on Dr. Reddy's Laboratories Underperform, Target Price ₹1,040, citing an unfavourable risk-reward despite optimistic assumptions of higher Canada semaglutide market share and an early US abatacept launch, with only modest upside even in a bullish scenario.
01 Jul 2026 09:08 AM
Dr. Reddy's Lab: Jefferies on Dr. Reddy's Laboratories Underperform, Target Price ₹1,040, citing an unfavourable risk-reward despite optimistic assumptions of higher Canada semaglutide market share and an early US abatacept launch, with only modest upside even in a bullish scenario.
Dr. Reddy's: Nomura on Dr. Reddy's Laboratories Buy, Target Price ₹1,740, citing encouraging US FDA inspection outcomes with seven observations mainly related to the new biosimilar block, indicating legacy contamination issues may be largely resolved, while management remains confident of resolving observations and launching biosimilar abatacept in 4QFY27.
29 Jun 2026 08:56 AM
Dr. Reddy's: Nomura on Dr. Reddy's Laboratories Buy, Target Price ₹1,740, citing encouraging US FDA inspection outcomes with seven observations mainly related to the new biosimilar block, indicating legacy contamination issues may be largely resolved, while management remains confident of resolving observations and launching biosimilar abatacept in 4QFY27.
Dr. Reddy's Labs: USFDA Finishes Pre-License Inspection Of Dr. Reddy's Labs' Biologics Manufacturing In Hyderabad, Noting Seven Observations.
26 Jun 2026 10:07 AM
Dr. Reddy's Labs: USFDA Finishes Pre-License Inspection Of Dr. Reddy's Labs' Biologics Manufacturing In Hyderabad, Noting Seven Observations.
Nomura on Dr Reddy's Laboratories – Buy | TP upgraded to ₹1,740 | Strategic shift towards branded generics and consumer business expected to support sustainable earnings growth and valuation re-rating.
22 Jun 2026 09:10 AM
Nomura on Dr Reddy's Laboratories – Buy | TP upgraded to ₹1,740 | Strategic shift towards branded generics and consumer business expected to support sustainable earnings growth and valuation re-rating.
Dr. Reddy's Lab: Nomura maintains a Buy on Dr. Reddy's Laboratories with a Target Price of ₹1,600, citing the positive surprise launch of gBosulif (Bosutinib 400mg) in the US with 180-day exclusivity via MSN partnership, targeting a USD214mn market and expected FY26 revenue contribution of USD25–30mn despite 30–40% price erosion.
15 Jun 2026 08:57 AM
Dr. Reddy's Lab: Nomura maintains a Buy on Dr. Reddy's Laboratories with a Target Price of ₹1,600, citing the positive surprise launch of gBosulif (Bosutinib 400mg) in the US with 180-day exclusivity via MSN partnership, targeting a USD214mn market and expected FY26 revenue contribution of USD25–30mn despite 30–40% price erosion.
Dr Reddy's Laboratories: Co Launches Bosutinib Tablets 400mg First In The U.S. To Boost Oncology Range; Exclusive Marketing Rights With Collaboration From MSN Laboratories.
13 Jun 2026 01:37 PM
Dr Reddy's Laboratories: Co Launches Bosutinib Tablets 400mg First In The U.S. To Boost Oncology Range; Exclusive Marketing Rights With Collaboration From MSN Laboratories.
Dr. Reddy's Lab: Launches Oral Semaglutide Biosimilar For Type 2 Diabetes In India - BL
21 May 2026 09:03 AM
Dr. Reddy's Lab: Launches Oral Semaglutide Biosimilar For Type 2 Diabetes In India - BL
Dr. Reddy's Laboratories: Co launches its generic semaglutide injection in Canada
16 May 2026 07:04 AM
Dr. Reddy's Laboratories: Co launches its generic semaglutide injection in Canada
Dr Reddy's Labs: Anticipates Continued Double-Digit Growth For Its Core Business Next Year, With Gross Margins Projected To Exceed 50% In FY '27 Due To Cost Savings, Increased Efficiency, And New Product Introductions Like Semaglutide.
13 May 2026 09:04 AM
Dr Reddy's Labs: Anticipates Continued Double-Digit Growth For Its Core Business Next Year, With Gross Margins Projected To Exceed 50% In FY '27 Due To Cost Savings, Increased Efficiency, And New Product Introductions Like Semaglutide.
Dr Reddy's Labs: Expects SG&A Expenses To Stay Around FY '26 Levels, R&D Spending Projected At 7% To 8% Of Adjusted Revenues, With Effective Tax Rate Anticipated At 24% To 25% For FY '27. North America Anticipates Double-Digit Growth Excluding Lenalidomide, With Additional Sales From Semaglutide.
13 May 2026 09:04 AM
Dr Reddy's Labs: Expects SG&A Expenses To Stay Around FY '26 Levels, R&D Spending Projected At 7% To 8% Of Adjusted Revenues, With Effective Tax Rate Anticipated At 24% To 25% For FY '27. North America Anticipates Double-Digit Growth Excluding Lenalidomide, With Additional Sales From Semaglutide.
Dr. Reddy's Labs: Plans To Keep EBITDA Margin Around 20% Without Semaglutide, Expecting It To Rise To About 25% With Semaglutide Sales. Sales Could Reach 6-7 Million Units By End Of 2026 And Target 10-11 Million Pens Per Quarter For FY 2027, Possibly Extending Into FY 2028 Due To Delays.
13 May 2026 09:04 AM
Dr. Reddy's Labs: Plans To Keep EBITDA Margin Around 20% Without Semaglutide, Expecting It To Rise To About 25% With Semaglutide Sales. Sales Could Reach 6-7 Million Units By End Of 2026 And Target 10-11 Million Pens Per Quarter For FY 2027, Possibly Extending Into FY 2028 Due To Delays.
Dr Reddy's Labs: Anticipates Semaglutide Pricing Around $30+ Per Unit, With A Minimum Price Of $25, And Higher Prices Possible In Some Markets. Annual Biosimilar Sales Are Expected To Reach Between $0.5 Billion And $700 Million By FY '29, Depending On Abatacept's Performance. Projected Capital Expenditure For Next Year (FY '27) Is Approximately INR 2,000 Crores.
13 May 2026 09:04 AM
Dr Reddy's Labs: Anticipates Semaglutide Pricing Around $30+ Per Unit, With A Minimum Price Of $25, And Higher Prices Possible In Some Markets. Annual Biosimilar Sales Are Expected To Reach Between $0.5 Billion And $700 Million By FY '29, Depending On Abatacept's Performance. Projected Capital Expenditure For Next Year (FY '27) Is Approximately INR 2,000 Crores.
Dr. Reddy's Lab: Plans To Launch Generic Version Of Oral Semaglutide Soon. - ET
13 May 2026 08:50 AM
Dr. Reddy's Lab: Plans To Launch Generic Version Of Oral Semaglutide Soon. - ET
Dr. Reddy’s: Nomura maintains a Buy on Dr. Reddy’s with a Target Price of ₹1600, noting Q4 sales were slightly ahead of estimates despite EBITDA being marginally below, while management expects sustained double-digit revenue growth across markets, improving gross margins to 50–55%, and EBITDA margins around 20% excluding Semaglutide contributions.
13 May 2026 08:41 AM
Dr. Reddy’s: Nomura maintains a Buy on Dr. Reddy’s with a Target Price of ₹1600, noting Q4 sales were slightly ahead of estimates despite EBITDA being marginally below, while management expects sustained double-digit revenue growth across markets, improving gross margins to 50–55%, and EBITDA margins around 20% excluding Semaglutide contributions.
Dr. Reddy’s: Morgan Stanley maintains an Equal-weight on Dr. Reddy’s with a Target Price of ₹1215, citing adjusted revenue and EBITDA missing estimates by 2% and 13% respectively, while noting a slight delay in Semaglutide ramp-up pending Brazil approval, though the company expects 6–7 million pen sales in CY2026 and plans to scale capacity beyond 40 million by FY28.
13 May 2026 08:41 AM
Dr. Reddy’s: Morgan Stanley maintains an Equal-weight on Dr. Reddy’s with a Target Price of ₹1215, citing adjusted revenue and EBITDA missing estimates by 2% and 13% respectively, while noting a slight delay in Semaglutide ramp-up pending Brazil approval, though the company expects 6–7 million pen sales in CY2026 and plans to scale capacity beyond 40 million by FY28.
Dr. Reddy’s: Jefferies maintains an Underperform on Dr. Reddy’s with a Target Price of ₹1040, citing a weak March quarter with material misses even after adjusting for one-offs, margin pressure from weak US performance and high SG&A costs despite growth in India, Russia and Europe, while management’s FY27 double-digit revenue growth guidance excluding gRevlimid remains in line, though slower Semaglutide uptake in Canada and delays in Abatacept launches pose downside risks.
13 May 2026 08:41 AM
Dr. Reddy’s: Jefferies maintains an Underperform on Dr. Reddy’s with a Target Price of ₹1040, citing a weak March quarter with material misses even after adjusting for one-offs, margin pressure from weak US performance and high SG&A costs despite growth in India, Russia and Europe, while management’s FY27 double-digit revenue growth guidance excluding gRevlimid remains in line, though slower Semaglutide uptake in Canada and delays in Abatacept launches pose downside risks.
Dr. Reddy: Labs Plans To Introduce Oral And Injectable Semaglutide In All Markets In The Future.
12 May 2026 06:28 PM
Dr. Reddy: Labs Plans To Introduce Oral And Injectable Semaglutide In All Markets In The Future.
Dr Reddy: Labs Plans To Launch Semaglutide In Canada And India Soon This Month.
12 May 2026 05:59 PM
Dr Reddy: Labs Plans To Launch Semaglutide In Canada And India Soon This Month.
